nodes	percent_of_prediction	percent_of_DWPC	metapath
Levobunolol—ADRB2—prostate cancer	0.732	1	CbGaD
Levobunolol—Timolol—ADRB2—prostate cancer	0.000984	0.128	CrCbGaD
Levobunolol—Carteolol—ADRB2—prostate cancer	0.000877	0.114	CrCbGaD
Levobunolol—Timolol—CYP2C19—prostate cancer	0.000847	0.11	CrCbGaD
Levobunolol—Nadolol—ADRB2—prostate cancer	0.000782	0.101	CrCbGaD
Levobunolol—Bupranolol—ADRB2—prostate cancer	0.000746	0.0967	CrCbGaD
Levobunolol—Salbutamol—ADRB2—prostate cancer	0.000701	0.0909	CrCbGaD
Levobunolol—Penbutolol—ADRB2—prostate cancer	0.000682	0.0885	CrCbGaD
Levobunolol—Pindolol—ADRB2—prostate cancer	0.000492	0.0638	CrCbGaD
Levobunolol—Chest pain—Conjugated Estrogens—prostate cancer	0.00049	0.00199	CcSEcCtD
Levobunolol—Asthenia—Bicalutamide—prostate cancer	0.000489	0.00199	CcSEcCtD
Levobunolol—Diabetes mellitus—Prednisone—prostate cancer	0.000488	0.00198	CcSEcCtD
Levobunolol—Lethargy—Capecitabine—prostate cancer	0.000486	0.00198	CcSEcCtD
Levobunolol—Cerebrovascular accident—Capecitabine—prostate cancer	0.000486	0.00198	CcSEcCtD
Levobunolol—Pruritus—Bicalutamide—prostate cancer	0.000482	0.00196	CcSEcCtD
Levobunolol—Confusional state—Goserelin—prostate cancer	0.000478	0.00194	CcSEcCtD
Levobunolol—Diplopia—Capecitabine—prostate cancer	0.000477	0.00194	CcSEcCtD
Levobunolol—Feeling abnormal—Ethinyl Estradiol—prostate cancer	0.000474	0.00193	CcSEcCtD
Levobunolol—Nausea—Cabazitaxel—prostate cancer	0.000472	0.00192	CcSEcCtD
Levobunolol—Atrioventricular block—Epirubicin—prostate cancer	0.000472	0.00192	CcSEcCtD
Levobunolol—Cardiac failure congestive—Prednisone—prostate cancer	0.000468	0.0019	CcSEcCtD
Levobunolol—Alopecia—Estradiol—prostate cancer	0.000467	0.0019	CcSEcCtD
Levobunolol—Shock—Goserelin—prostate cancer	0.000466	0.0019	CcSEcCtD
Levobunolol—Diarrhoea—Bicalutamide—prostate cancer	0.000466	0.0019	CcSEcCtD
Levobunolol—Ataxia—Docetaxel—prostate cancer	0.000463	0.00188	CcSEcCtD
Levobunolol—Shock—Conjugated Estrogens—prostate cancer	0.000462	0.00188	CcSEcCtD
Levobunolol—Urticaria—Ethinyl Estradiol—prostate cancer	0.000457	0.00186	CcSEcCtD
Levobunolol—Cardiac arrest—Capecitabine—prostate cancer	0.000453	0.00184	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Etoposide—prostate cancer	0.000453	0.00184	CcSEcCtD
Levobunolol—Dizziness—Bicalutamide—prostate cancer	0.00045	0.00183	CcSEcCtD
Levobunolol—Ataxia—Capecitabine—prostate cancer	0.000448	0.00182	CcSEcCtD
Levobunolol—Hypotension—Goserelin—prostate cancer	0.000443	0.0018	CcSEcCtD
Levobunolol—Arrhythmia—Mitoxantrone—prostate cancer	0.00044	0.00179	CcSEcCtD
Levobunolol—Hypotension—Conjugated Estrogens—prostate cancer	0.000439	0.00178	CcSEcCtD
Levobunolol—Atrioventricular block—Doxorubicin—prostate cancer	0.000436	0.00177	CcSEcCtD
Levobunolol—Alopecia—Mitoxantrone—prostate cancer	0.000435	0.00177	CcSEcCtD
Levobunolol—Lethargy—Prednisone—prostate cancer	0.000433	0.00176	CcSEcCtD
Levobunolol—Headache—Bicalutamide—prostate cancer	0.000427	0.00174	CcSEcCtD
Levobunolol—Paraesthesia—Goserelin—prostate cancer	0.000426	0.00173	CcSEcCtD
Levobunolol—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000424	0.00172	CcSEcCtD
Levobunolol—Dyspnoea—Goserelin—prostate cancer	0.000422	0.00172	CcSEcCtD
Levobunolol—Paraesthesia—Conjugated Estrogens—prostate cancer	0.000421	0.00171	CcSEcCtD
Levobunolol—Bronchospasm—Docetaxel—prostate cancer	0.000419	0.0017	CcSEcCtD
Levobunolol—Dyspnoea—Conjugated Estrogens—prostate cancer	0.000418	0.0017	CcSEcCtD
Levobunolol—Asthenia—Ethinyl Estradiol—prostate cancer	0.000413	0.00168	CcSEcCtD
Levobunolol—Syncope—Estradiol—prostate cancer	0.000413	0.00168	CcSEcCtD
Levobunolol—Pruritus—Ethinyl Estradiol—prostate cancer	0.000407	0.00166	CcSEcCtD
Levobunolol—Palpitations—Estradiol—prostate cancer	0.000407	0.00165	CcSEcCtD
Levobunolol—Pain—Goserelin—prostate cancer	0.000405	0.00165	CcSEcCtD
Levobunolol—Bronchospasm—Capecitabine—prostate cancer	0.000405	0.00165	CcSEcCtD
Levobunolol—Nausea—Bicalutamide—prostate cancer	0.000405	0.00165	CcSEcCtD
Levobunolol—Loss of consciousness—Estradiol—prostate cancer	0.000405	0.00165	CcSEcCtD
Levobunolol—Cardiac arrest—Prednisone—prostate cancer	0.000404	0.00164	CcSEcCtD
Levobunolol—Pain—Conjugated Estrogens—prostate cancer	0.000401	0.00163	CcSEcCtD
Levobunolol—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000394	0.0016	CcSEcCtD
Levobunolol—Chest pain—Estradiol—prostate cancer	0.000392	0.00159	CcSEcCtD
Levobunolol—Feeling abnormal—Goserelin—prostate cancer	0.00039	0.00159	CcSEcCtD
Levobunolol—Erythema multiforme—Etoposide—prostate cancer	0.000387	0.00158	CcSEcCtD
Levobunolol—Salbutamol—CYP3A4—prostate cancer	0.000384	0.0498	CrCbGaD
Levobunolol—Diabetes mellitus—Epirubicin—prostate cancer	0.000382	0.00155	CcSEcCtD
Levobunolol—Dizziness—Ethinyl Estradiol—prostate cancer	0.000381	0.00155	CcSEcCtD
Levobunolol—Confusional state—Estradiol—prostate cancer	0.000379	0.00154	CcSEcCtD
Levobunolol—Urticaria—Goserelin—prostate cancer	0.000376	0.00153	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Docetaxel—prostate cancer	0.000376	0.00153	CcSEcCtD
Levobunolol—Urticaria—Conjugated Estrogens—prostate cancer	0.000373	0.00152	CcSEcCtD
Levobunolol—Shock—Estradiol—prostate cancer	0.00037	0.0015	CcSEcCtD
Levobunolol—Conjunctivitis—Docetaxel—prostate cancer	0.000369	0.0015	CcSEcCtD
Levobunolol—Depression—Capecitabine—prostate cancer	0.000366	0.00149	CcSEcCtD
Levobunolol—Cardiac failure congestive—Epirubicin—prostate cancer	0.000366	0.00149	CcSEcCtD
Levobunolol—Chest pain—Mitoxantrone—prostate cancer	0.000365	0.00148	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Capecitabine—prostate cancer	0.000364	0.00148	CcSEcCtD
Levobunolol—Alopecia—Etoposide—prostate cancer	0.000362	0.00147	CcSEcCtD
Levobunolol—Headache—Ethinyl Estradiol—prostate cancer	0.000361	0.00147	CcSEcCtD
Levobunolol—Conjunctivitis—Capecitabine—prostate cancer	0.000357	0.00145	CcSEcCtD
Levobunolol—Diabetes mellitus—Doxorubicin—prostate cancer	0.000353	0.00144	CcSEcCtD
Levobunolol—Confusional state—Mitoxantrone—prostate cancer	0.000353	0.00144	CcSEcCtD
Levobunolol—Hypersensitivity—Goserelin—prostate cancer	0.000349	0.00142	CcSEcCtD
Levobunolol—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000346	0.00141	CcSEcCtD
Levobunolol—Shock—Mitoxantrone—prostate cancer	0.000344	0.0014	CcSEcCtD
Levobunolol—Nausea—Ethinyl Estradiol—prostate cancer	0.000342	0.00139	CcSEcCtD
Levobunolol—Hypoglycaemia—Epirubicin—prostate cancer	0.00034	0.00138	CcSEcCtD
Levobunolol—Asthenia—Goserelin—prostate cancer	0.00034	0.00138	CcSEcCtD
Levobunolol—Propranolol—CYP3A5—prostate cancer	0.000339	0.044	CrCbGaD
Levobunolol—Lethargy—Epirubicin—prostate cancer	0.000339	0.00138	CcSEcCtD
Levobunolol—Cerebrovascular accident—Epirubicin—prostate cancer	0.000339	0.00138	CcSEcCtD
Levobunolol—Cardiac failure congestive—Doxorubicin—prostate cancer	0.000339	0.00138	CcSEcCtD
Levobunolol—Erectile dysfunction—Prednisone—prostate cancer	0.000338	0.00137	CcSEcCtD
Levobunolol—Paraesthesia—Estradiol—prostate cancer	0.000337	0.00137	CcSEcCtD
Levobunolol—Asthenia—Conjugated Estrogens—prostate cancer	0.000337	0.00137	CcSEcCtD
Levobunolol—Bradycardia—Capecitabine—prostate cancer	0.000336	0.00136	CcSEcCtD
Levobunolol—Pruritus—Goserelin—prostate cancer	0.000335	0.00136	CcSEcCtD
Levobunolol—Dyspnoea—Estradiol—prostate cancer	0.000335	0.00136	CcSEcCtD
Levobunolol—Pruritus—Conjugated Estrogens—prostate cancer	0.000332	0.00135	CcSEcCtD
Levobunolol—Diplopia—Epirubicin—prostate cancer	0.000332	0.00135	CcSEcCtD
Levobunolol—Visual impairment—Docetaxel—prostate cancer	0.000328	0.00133	CcSEcCtD
Levobunolol—Hypotension—Mitoxantrone—prostate cancer	0.000327	0.00133	CcSEcCtD
Levobunolol—Depression—Prednisone—prostate cancer	0.000326	0.00133	CcSEcCtD
Levobunolol—Diarrhoea—Goserelin—prostate cancer	0.000324	0.00132	CcSEcCtD
Levobunolol—Erythema multiforme—Docetaxel—prostate cancer	0.000322	0.00131	CcSEcCtD
Levobunolol—Pain—Estradiol—prostate cancer	0.000321	0.00131	CcSEcCtD
Levobunolol—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000321	0.00131	CcSEcCtD
Levobunolol—Visual impairment—Capecitabine—prostate cancer	0.000318	0.00129	CcSEcCtD
Levobunolol—Cardiac arrest—Epirubicin—prostate cancer	0.000316	0.00128	CcSEcCtD
Levobunolol—Hypoglycaemia—Doxorubicin—prostate cancer	0.000315	0.00128	CcSEcCtD
Levobunolol—Paraesthesia—Mitoxantrone—prostate cancer	0.000314	0.00128	CcSEcCtD
Levobunolol—Loss of consciousness—Etoposide—prostate cancer	0.000314	0.00127	CcSEcCtD
Levobunolol—Lethargy—Doxorubicin—prostate cancer	0.000314	0.00127	CcSEcCtD
Levobunolol—Cerebrovascular accident—Doxorubicin—prostate cancer	0.000314	0.00127	CcSEcCtD
Levobunolol—Dizziness—Goserelin—prostate cancer	0.000313	0.00127	CcSEcCtD
Levobunolol—Ataxia—Epirubicin—prostate cancer	0.000312	0.00127	CcSEcCtD
Levobunolol—Dyspnoea—Mitoxantrone—prostate cancer	0.000312	0.00127	CcSEcCtD
Levobunolol—Erythema multiforme—Capecitabine—prostate cancer	0.000312	0.00127	CcSEcCtD
Levobunolol—Dizziness—Conjugated Estrogens—prostate cancer	0.00031	0.00126	CcSEcCtD
Levobunolol—Feeling abnormal—Estradiol—prostate cancer	0.00031	0.00126	CcSEcCtD
Levobunolol—Diplopia—Doxorubicin—prostate cancer	0.000307	0.00125	CcSEcCtD
Levobunolol—Arrhythmia—Docetaxel—prostate cancer	0.000304	0.00124	CcSEcCtD
Levobunolol—Chest pain—Etoposide—prostate cancer	0.000304	0.00123	CcSEcCtD
Levobunolol—Alopecia—Docetaxel—prostate cancer	0.000301	0.00122	CcSEcCtD
Levobunolol—Pain—Mitoxantrone—prostate cancer	0.000299	0.00122	CcSEcCtD
Levobunolol—Bradycardia—Prednisone—prostate cancer	0.000299	0.00122	CcSEcCtD
Levobunolol—Urticaria—Estradiol—prostate cancer	0.000298	0.00121	CcSEcCtD
Levobunolol—Headache—Goserelin—prostate cancer	0.000297	0.00121	CcSEcCtD
Levobunolol—Arrhythmia—Capecitabine—prostate cancer	0.000295	0.0012	CcSEcCtD
Levobunolol—Headache—Conjugated Estrogens—prostate cancer	0.000294	0.0012	CcSEcCtD
Levobunolol—Confusional state—Etoposide—prostate cancer	0.000294	0.00119	CcSEcCtD
Levobunolol—Cardiac arrest—Doxorubicin—prostate cancer	0.000292	0.00119	CcSEcCtD
Levobunolol—Alopecia—Capecitabine—prostate cancer	0.000291	0.00118	CcSEcCtD
Levobunolol—Ataxia—Doxorubicin—prostate cancer	0.000289	0.00117	CcSEcCtD
Levobunolol—Feeling abnormal—Mitoxantrone—prostate cancer	0.000288	0.00117	CcSEcCtD
Levobunolol—Nausea—Goserelin—prostate cancer	0.000281	0.00114	CcSEcCtD
Levobunolol—Nausea—Conjugated Estrogens—prostate cancer	0.000279	0.00113	CcSEcCtD
Levobunolol—Urticaria—Mitoxantrone—prostate cancer	0.000278	0.00113	CcSEcCtD
Levobunolol—Hypersensitivity—Estradiol—prostate cancer	0.000277	0.00113	CcSEcCtD
Levobunolol—Hypotension—Etoposide—prostate cancer	0.000272	0.00111	CcSEcCtD
Levobunolol—Asthenia—Estradiol—prostate cancer	0.00027	0.0011	CcSEcCtD
Levobunolol—Propranolol—ADRB2—prostate cancer	0.000268	0.0348	CrCbGaD
Levobunolol—Syncope—Docetaxel—prostate cancer	0.000266	0.00108	CcSEcCtD
Levobunolol—Pruritus—Estradiol—prostate cancer	0.000266	0.00108	CcSEcCtD
Levobunolol—Arrhythmia—Prednisone—prostate cancer	0.000262	0.00107	CcSEcCtD
Levobunolol—Palpitations—Docetaxel—prostate cancer	0.000262	0.00107	CcSEcCtD
Levobunolol—Paraesthesia—Etoposide—prostate cancer	0.000261	0.00106	CcSEcCtD
Levobunolol—Loss of consciousness—Docetaxel—prostate cancer	0.000261	0.00106	CcSEcCtD
Levobunolol—Dyspnoea—Etoposide—prostate cancer	0.00026	0.00106	CcSEcCtD
Levobunolol—Alopecia—Prednisone—prostate cancer	0.00026	0.00106	CcSEcCtD
Levobunolol—Hypersensitivity—Mitoxantrone—prostate cancer	0.000258	0.00105	CcSEcCtD
Levobunolol—Syncope—Capecitabine—prostate cancer	0.000257	0.00105	CcSEcCtD
Levobunolol—Diarrhoea—Estradiol—prostate cancer	0.000257	0.00105	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000254	0.00103	CcSEcCtD
Levobunolol—Palpitations—Capecitabine—prostate cancer	0.000254	0.00103	CcSEcCtD
Levobunolol—Chest pain—Docetaxel—prostate cancer	0.000252	0.00103	CcSEcCtD
Levobunolol—Loss of consciousness—Capecitabine—prostate cancer	0.000252	0.00103	CcSEcCtD
Levobunolol—Asthenia—Mitoxantrone—prostate cancer	0.000251	0.00102	CcSEcCtD
Levobunolol—Pain—Etoposide—prostate cancer	0.000249	0.00101	CcSEcCtD
Levobunolol—Conjunctivitis—Epirubicin—prostate cancer	0.000249	0.00101	CcSEcCtD
Levobunolol—Dizziness—Estradiol—prostate cancer	0.000248	0.00101	CcSEcCtD
Levobunolol—Chest pain—Capecitabine—prostate cancer	0.000244	0.000994	CcSEcCtD
Levobunolol—Confusional state—Docetaxel—prostate cancer	0.000244	0.000992	CcSEcCtD
Levobunolol—Feeling abnormal—Etoposide—prostate cancer	0.00024	0.000976	CcSEcCtD
Levobunolol—Diarrhoea—Mitoxantrone—prostate cancer	0.000239	0.000974	CcSEcCtD
Levobunolol—Shock—Docetaxel—prostate cancer	0.000238	0.000968	CcSEcCtD
Levobunolol—Confusional state—Capecitabine—prostate cancer	0.000236	0.000961	CcSEcCtD
Levobunolol—Headache—Estradiol—prostate cancer	0.000235	0.000957	CcSEcCtD
Levobunolol—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000235	0.000955	CcSEcCtD
Levobunolol—Bradycardia—Epirubicin—prostate cancer	0.000234	0.000951	CcSEcCtD
Levobunolol—Urticaria—Etoposide—prostate cancer	0.000231	0.000941	CcSEcCtD
Levobunolol—Propranolol—CYP2C19—prostate cancer	0.000231	0.0299	CrCbGaD
Levobunolol—Shock—Capecitabine—prostate cancer	0.00023	0.000937	CcSEcCtD
Levobunolol—Conjunctivitis—Doxorubicin—prostate cancer	0.00023	0.000936	CcSEcCtD
Levobunolol—Propranolol—CYP1A1—prostate cancer	0.00023	0.0298	CrCbGaD
Levobunolol—Syncope—Prednisone—prostate cancer	0.000229	0.000932	CcSEcCtD
Levobunolol—Hypotension—Docetaxel—prostate cancer	0.000226	0.000919	CcSEcCtD
Levobunolol—Loss of consciousness—Prednisone—prostate cancer	0.000225	0.000914	CcSEcCtD
Levobunolol—Nausea—Estradiol—prostate cancer	0.000223	0.000907	CcSEcCtD
Levobunolol—Visual impairment—Epirubicin—prostate cancer	0.000221	0.0009	CcSEcCtD
Levobunolol—Headache—Mitoxantrone—prostate cancer	0.000219	0.000892	CcSEcCtD
Levobunolol—Hypotension—Capecitabine—prostate cancer	0.000219	0.00089	CcSEcCtD
Levobunolol—Paraesthesia—Docetaxel—prostate cancer	0.000217	0.000883	CcSEcCtD
Levobunolol—Erythema multiforme—Epirubicin—prostate cancer	0.000217	0.000883	CcSEcCtD
Levobunolol—Bradycardia—Doxorubicin—prostate cancer	0.000216	0.00088	CcSEcCtD
Levobunolol—Dyspnoea—Docetaxel—prostate cancer	0.000216	0.000877	CcSEcCtD
Levobunolol—Hypersensitivity—Etoposide—prostate cancer	0.000215	0.000872	CcSEcCtD
Levobunolol—Paraesthesia—Capecitabine—prostate cancer	0.00021	0.000855	CcSEcCtD
Levobunolol—Asthenia—Etoposide—prostate cancer	0.000209	0.000849	CcSEcCtD
Levobunolol—Dyspnoea—Capecitabine—prostate cancer	0.000209	0.000849	CcSEcCtD
Levobunolol—Nausea—Mitoxantrone—prostate cancer	0.000208	0.000845	CcSEcCtD
Levobunolol—Pain—Docetaxel—prostate cancer	0.000207	0.000841	CcSEcCtD
Levobunolol—Pruritus—Etoposide—prostate cancer	0.000206	0.000838	CcSEcCtD
Levobunolol—Shock—Prednisone—prostate cancer	0.000205	0.000835	CcSEcCtD
Levobunolol—Arrhythmia—Epirubicin—prostate cancer	0.000205	0.000834	CcSEcCtD
Levobunolol—Visual impairment—Doxorubicin—prostate cancer	0.000205	0.000833	CcSEcCtD
Levobunolol—Alopecia—Epirubicin—prostate cancer	0.000203	0.000825	CcSEcCtD
Levobunolol—Erythema multiforme—Doxorubicin—prostate cancer	0.000201	0.000817	CcSEcCtD
Levobunolol—Pain—Capecitabine—prostate cancer	0.0002	0.000815	CcSEcCtD
Levobunolol—Feeling abnormal—Docetaxel—prostate cancer	0.000199	0.000811	CcSEcCtD
Levobunolol—Diarrhoea—Etoposide—prostate cancer	0.000199	0.00081	CcSEcCtD
Levobunolol—Feeling abnormal—Capecitabine—prostate cancer	0.000193	0.000785	CcSEcCtD
Levobunolol—Dizziness—Etoposide—prostate cancer	0.000193	0.000783	CcSEcCtD
Levobunolol—Arrhythmia—Doxorubicin—prostate cancer	0.00019	0.000772	CcSEcCtD
Levobunolol—Alopecia—Doxorubicin—prostate cancer	0.000188	0.000764	CcSEcCtD
Levobunolol—Paraesthesia—Prednisone—prostate cancer	0.000187	0.000762	CcSEcCtD
Levobunolol—Urticaria—Capecitabine—prostate cancer	0.000186	0.000757	CcSEcCtD
Levobunolol—Headache—Etoposide—prostate cancer	0.000182	0.000742	CcSEcCtD
Levobunolol—Syncope—Epirubicin—prostate cancer	0.000179	0.000729	CcSEcCtD
Levobunolol—Hypersensitivity—Docetaxel—prostate cancer	0.000178	0.000725	CcSEcCtD
Levobunolol—Palpitations—Epirubicin—prostate cancer	0.000177	0.000719	CcSEcCtD
Levobunolol—Loss of consciousness—Epirubicin—prostate cancer	0.000176	0.000715	CcSEcCtD
Levobunolol—Asthenia—Docetaxel—prostate cancer	0.000174	0.000706	CcSEcCtD
Levobunolol—Nausea—Etoposide—prostate cancer	0.000173	0.000703	CcSEcCtD
Levobunolol—Hypersensitivity—Capecitabine—prostate cancer	0.000173	0.000702	CcSEcCtD
Levobunolol—Feeling abnormal—Prednisone—prostate cancer	0.000172	0.000699	CcSEcCtD
Levobunolol—Pruritus—Docetaxel—prostate cancer	0.000171	0.000696	CcSEcCtD
Levobunolol—Chest pain—Epirubicin—prostate cancer	0.00017	0.000692	CcSEcCtD
Levobunolol—Asthenia—Capecitabine—prostate cancer	0.000168	0.000683	CcSEcCtD
Levobunolol—Syncope—Doxorubicin—prostate cancer	0.000166	0.000675	CcSEcCtD
Levobunolol—Urticaria—Prednisone—prostate cancer	0.000166	0.000674	CcSEcCtD
Levobunolol—Pruritus—Capecitabine—prostate cancer	0.000166	0.000674	CcSEcCtD
Levobunolol—Diarrhoea—Docetaxel—prostate cancer	0.000166	0.000673	CcSEcCtD
Levobunolol—Confusional state—Epirubicin—prostate cancer	0.000165	0.000669	CcSEcCtD
Levobunolol—Palpitations—Doxorubicin—prostate cancer	0.000164	0.000665	CcSEcCtD
Levobunolol—Loss of consciousness—Doxorubicin—prostate cancer	0.000163	0.000661	CcSEcCtD
Levobunolol—Shock—Epirubicin—prostate cancer	0.000161	0.000653	CcSEcCtD
Levobunolol—Diarrhoea—Capecitabine—prostate cancer	0.00016	0.000652	CcSEcCtD
Levobunolol—Dizziness—Docetaxel—prostate cancer	0.00016	0.000651	CcSEcCtD
Levobunolol—Chest pain—Doxorubicin—prostate cancer	0.000158	0.000641	CcSEcCtD
Levobunolol—Dizziness—Capecitabine—prostate cancer	0.000155	0.00063	CcSEcCtD
Levobunolol—Hypersensitivity—Prednisone—prostate cancer	0.000154	0.000625	CcSEcCtD
Levobunolol—Hypotension—Epirubicin—prostate cancer	0.000153	0.00062	CcSEcCtD
Levobunolol—Confusional state—Doxorubicin—prostate cancer	0.000152	0.000619	CcSEcCtD
Levobunolol—Headache—Docetaxel—prostate cancer	0.000152	0.000616	CcSEcCtD
Levobunolol—Asthenia—Prednisone—prostate cancer	0.00015	0.000609	CcSEcCtD
Levobunolol—Shock—Doxorubicin—prostate cancer	0.000149	0.000604	CcSEcCtD
Levobunolol—Pruritus—Prednisone—prostate cancer	0.000148	0.0006	CcSEcCtD
Levobunolol—Propranolol—CYP3A4—prostate cancer	0.000147	0.019	CrCbGaD
Levobunolol—Headache—Capecitabine—prostate cancer	0.000147	0.000597	CcSEcCtD
Levobunolol—Paraesthesia—Epirubicin—prostate cancer	0.000147	0.000596	CcSEcCtD
Levobunolol—Dyspnoea—Epirubicin—prostate cancer	0.000146	0.000592	CcSEcCtD
Levobunolol—Nausea—Docetaxel—prostate cancer	0.000144	0.000584	CcSEcCtD
Levobunolol—Diarrhoea—Prednisone—prostate cancer	0.000143	0.000581	CcSEcCtD
Levobunolol—Hypotension—Doxorubicin—prostate cancer	0.000141	0.000574	CcSEcCtD
Levobunolol—Pain—Epirubicin—prostate cancer	0.00014	0.000568	CcSEcCtD
Levobunolol—Nausea—Capecitabine—prostate cancer	0.000139	0.000566	CcSEcCtD
Levobunolol—Dizziness—Prednisone—prostate cancer	0.000138	0.000561	CcSEcCtD
Levobunolol—Paraesthesia—Doxorubicin—prostate cancer	0.000136	0.000551	CcSEcCtD
Levobunolol—Dyspnoea—Doxorubicin—prostate cancer	0.000135	0.000547	CcSEcCtD
Levobunolol—Feeling abnormal—Epirubicin—prostate cancer	0.000134	0.000547	CcSEcCtD
Levobunolol—Headache—Prednisone—prostate cancer	0.000131	0.000532	CcSEcCtD
Levobunolol—Urticaria—Epirubicin—prostate cancer	0.00013	0.000527	CcSEcCtD
Levobunolol—Pain—Doxorubicin—prostate cancer	0.000129	0.000525	CcSEcCtD
Levobunolol—Feeling abnormal—Doxorubicin—prostate cancer	0.000124	0.000506	CcSEcCtD
Levobunolol—Nausea—Prednisone—prostate cancer	0.000124	0.000504	CcSEcCtD
Levobunolol—Hypersensitivity—Epirubicin—prostate cancer	0.00012	0.000489	CcSEcCtD
Levobunolol—Urticaria—Doxorubicin—prostate cancer	0.00012	0.000488	CcSEcCtD
Levobunolol—Asthenia—Epirubicin—prostate cancer	0.000117	0.000476	CcSEcCtD
Levobunolol—Pruritus—Epirubicin—prostate cancer	0.000115	0.00047	CcSEcCtD
Levobunolol—Diarrhoea—Epirubicin—prostate cancer	0.000112	0.000454	CcSEcCtD
Levobunolol—Hypersensitivity—Doxorubicin—prostate cancer	0.000111	0.000452	CcSEcCtD
Levobunolol—Asthenia—Doxorubicin—prostate cancer	0.000108	0.000441	CcSEcCtD
Levobunolol—Dizziness—Epirubicin—prostate cancer	0.000108	0.000439	CcSEcCtD
Levobunolol—Pruritus—Doxorubicin—prostate cancer	0.000107	0.000434	CcSEcCtD
Levobunolol—Diarrhoea—Doxorubicin—prostate cancer	0.000103	0.00042	CcSEcCtD
Levobunolol—Headache—Epirubicin—prostate cancer	0.000102	0.000416	CcSEcCtD
Levobunolol—Dizziness—Doxorubicin—prostate cancer	9.99e-05	0.000406	CcSEcCtD
Levobunolol—Nausea—Epirubicin—prostate cancer	9.69e-05	0.000394	CcSEcCtD
Levobunolol—Headache—Doxorubicin—prostate cancer	9.46e-05	0.000385	CcSEcCtD
Levobunolol—Nausea—Doxorubicin—prostate cancer	8.97e-05	0.000365	CcSEcCtD
Levobunolol—ADRB2—Signaling Pathways—MC2R—prostate cancer	1.7e-05	0.00119	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PTHLH—prostate cancer	1.69e-05	0.00118	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PRKACB—prostate cancer	1.65e-05	0.00116	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PTHLH—prostate cancer	1.65e-05	0.00115	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CALCA—prostate cancer	1.64e-05	0.00114	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PRKACB—prostate cancer	1.62e-05	0.00113	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PPP3CA—prostate cancer	1.61e-05	0.00113	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CALCA—prostate cancer	1.6e-05	0.00112	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CXCL12—prostate cancer	1.6e-05	0.00112	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—ANXA1—prostate cancer	1.59e-05	0.00111	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PPP3CA—prostate cancer	1.57e-05	0.0011	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CXCL12—prostate cancer	1.56e-05	0.00109	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—ANXA1—prostate cancer	1.55e-05	0.00109	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PENK—prostate cancer	1.55e-05	0.00108	CbGpPWpGaD
Levobunolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	1.54e-05	0.00108	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PENK—prostate cancer	1.51e-05	0.00106	CbGpPWpGaD
Levobunolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	1.5e-05	0.00105	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CALCA—prostate cancer	1.49e-05	0.00104	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GHR—prostate cancer	1.48e-05	0.00103	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PRKCQ—prostate cancer	1.46e-05	0.00102	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CALCA—prostate cancer	1.45e-05	0.00102	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CXCL12—prostate cancer	1.45e-05	0.00102	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GHR—prostate cancer	1.44e-05	0.00101	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PRKCQ—prostate cancer	1.43e-05	0.000998	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CXCL12—prostate cancer	1.42e-05	0.000993	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NRP1—prostate cancer	1.41e-05	0.00099	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NRP1—prostate cancer	1.38e-05	0.000968	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—ADRB2—prostate cancer	1.37e-05	0.000959	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—VAV3—prostate cancer	1.34e-05	0.000935	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PRKCQ—prostate cancer	1.32e-05	0.000926	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GNRH1—prostate cancer	1.32e-05	0.00092	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—VIP—prostate cancer	1.32e-05	0.00092	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—VAV3—prostate cancer	1.31e-05	0.000915	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—ITPR1—prostate cancer	1.3e-05	0.000907	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PRKCQ—prostate cancer	1.3e-05	0.000906	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GNRH1—prostate cancer	1.29e-05	0.0009	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—VIP—prostate cancer	1.29e-05	0.0009	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—LPAR1—prostate cancer	1.27e-05	0.000891	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GRP—prostate cancer	1.27e-05	0.000891	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—ITPR1—prostate cancer	1.27e-05	0.000887	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PLCB2—prostate cancer	1.26e-05	0.000882	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—LRP2—prostate cancer	1.26e-05	0.000882	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—LPAR1—prostate cancer	1.25e-05	0.000872	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GRP—prostate cancer	1.25e-05	0.000872	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—ADRB2—prostate cancer	1.24e-05	0.000871	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—P4HB—prostate cancer	1.24e-05	0.000865	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CX3CL1—prostate cancer	1.24e-05	0.000865	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PLCB2—prostate cancer	1.23e-05	0.000863	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—LRP2—prostate cancer	1.23e-05	0.000863	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—VAV3—prostate cancer	1.21e-05	0.000849	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HIST1H2BG—prostate cancer	1.21e-05	0.000849	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—P4HB—prostate cancer	1.21e-05	0.000846	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CX3CL1—prostate cancer	1.21e-05	0.000846	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PDE4D—prostate cancer	1.2e-05	0.000842	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GRB7—prostate cancer	1.2e-05	0.000842	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—VAV3—prostate cancer	1.19e-05	0.000831	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HIST1H2BG—prostate cancer	1.19e-05	0.000831	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—ITPR1—prostate cancer	1.18e-05	0.000824	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PDE4D—prostate cancer	1.18e-05	0.000823	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GRB7—prostate cancer	1.18e-05	0.000823	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HIST1H4H—prostate cancer	1.17e-05	0.00082	CbGpPWpGaD
Levobunolol—ADRB1—GPCR ligand binding—CXCL8—prostate cancer	1.17e-05	0.00082	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—ITPR1—prostate cancer	1.15e-05	0.000806	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HIST1H4H—prostate cancer	1.15e-05	0.000802	CbGpPWpGaD
Levobunolol—ADRB2—GPCR ligand binding—CXCL8—prostate cancer	1.15e-05	0.000802	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GNG5—prostate cancer	1.14e-05	0.000801	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GNG5—prostate cancer	1.12e-05	0.000783	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TGFBR1—prostate cancer	9.97e-06	0.000697	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTHLH—prostate cancer	9.97e-06	0.000697	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—AKR1C3—prostate cancer	9.8e-06	0.000686	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PRKACB—prostate cancer	9.75e-06	0.000682	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTHLH—prostate cancer	9.75e-06	0.000682	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TGFBR1—prostate cancer	9.75e-06	0.000682	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—AKR1C3—prostate cancer	9.59e-06	0.000671	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PRKACB—prostate cancer	9.54e-06	0.000668	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PPP3CA—prostate cancer	9.51e-06	0.000665	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—THBS1—prostate cancer	9.51e-06	0.000665	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ANXA1—prostate cancer	9.37e-06	0.000656	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—THBS1—prostate cancer	9.3e-06	0.000651	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PPP3CA—prostate cancer	9.3e-06	0.000651	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PRKCZ—prostate cancer	9.2e-06	0.000644	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ANXA1—prostate cancer	9.17e-06	0.000641	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PRKCZ—prostate cancer	9e-06	0.00063	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CG—prostate cancer	8.99e-06	0.000629	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FGFR4—prostate cancer	8.88e-06	0.000622	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PARP1—prostate cancer	8.88e-06	0.000622	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CG—prostate cancer	8.79e-06	0.000615	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CALCA—prostate cancer	8.77e-06	0.000614	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FGFR4—prostate cancer	8.69e-06	0.000608	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PARP1—prostate cancer	8.69e-06	0.000608	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CALCA—prostate cancer	8.58e-06	0.000601	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CXCL12—prostate cancer	8.57e-06	0.0006	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CXCL12—prostate cancer	8.38e-06	0.000587	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CG—prostate cancer	8.16e-06	0.000571	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CASP9—prostate cancer	8.07e-06	0.000565	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CG—prostate cancer	7.99e-06	0.000559	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CD—prostate cancer	7.9e-06	0.000553	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CASP9—prostate cancer	7.9e-06	0.000552	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PRKCQ—prostate cancer	7.82e-06	0.000547	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NGFR—prostate cancer	7.82e-06	0.000547	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CD—prostate cancer	7.73e-06	0.000541	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAP3K7—prostate cancer	7.73e-06	0.000541	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NGFR—prostate cancer	7.65e-06	0.000535	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PRKCQ—prostate cancer	7.65e-06	0.000535	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAP3K7—prostate cancer	7.56e-06	0.000529	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FGF10—prostate cancer	7.43e-06	0.00052	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ADRB2—prostate cancer	7.35e-06	0.000515	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FGF10—prostate cancer	7.27e-06	0.000509	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—JAK2—prostate cancer	7.25e-06	0.000508	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—MAP2K1—prostate cancer	7.22e-06	0.000506	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CD—prostate cancer	7.18e-06	0.000502	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—VAV3—prostate cancer	7.17e-06	0.000502	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—JAK2—prostate cancer	7.1e-06	0.000496	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TGFBR2—prostate cancer	7.07e-06	0.000495	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—MAP2K1—prostate cancer	7.07e-06	0.000495	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CD—prostate cancer	7.02e-06	0.000491	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—VAV3—prostate cancer	7.01e-06	0.000491	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ITPR1—prostate cancer	6.95e-06	0.000487	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	6.91e-06	0.000484	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CB—prostate cancer	6.89e-06	0.000482	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	6.8e-06	0.000476	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	6.74e-06	0.000472	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IGF1R—prostate cancer	6.65e-06	0.000465	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	6.62e-06	0.000463	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	6.59e-06	0.000461	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	6.5e-06	0.000455	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	6.48e-06	0.000453	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	6.44e-06	0.000451	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—LPL—prostate cancer	6.38e-06	0.000446	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	6.33e-06	0.000443	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	6.32e-06	0.000442	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	6.26e-06	0.000438	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—LPL—prostate cancer	6.24e-06	0.000436	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	6.19e-06	0.000433	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	6.18e-06	0.000432	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	6.16e-06	0.000431	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	6.12e-06	0.000428	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	6.02e-06	0.000421	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	6.01e-06	0.000421	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	5.97e-06	0.000418	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	5.96e-06	0.000417	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	5.88e-06	0.000411	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	5.84e-06	0.000409	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	5.83e-06	0.000408	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—IL2—prostate cancer	5.75e-06	0.000402	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TERT—prostate cancer	5.72e-06	0.000401	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—IL2—prostate cancer	5.62e-06	0.000393	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TERT—prostate cancer	5.6e-06	0.000392	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	5.47e-06	0.000383	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	5.35e-06	0.000375	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—LEP—prostate cancer	5.34e-06	0.000374	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CAV1—prostate cancer	5.29e-06	0.00037	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KDR—prostate cancer	5.24e-06	0.000366	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—LEP—prostate cancer	5.23e-06	0.000366	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CAV1—prostate cancer	5.18e-06	0.000362	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KDR—prostate cancer	5.12e-06	0.000358	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ESR1—prostate cancer	5.1e-06	0.000357	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ESR1—prostate cancer	4.99e-06	0.000349	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—BAD—prostate cancer	4.98e-06	0.000348	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—BAD—prostate cancer	4.87e-06	0.000341	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	4.82e-06	0.000337	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—APC—prostate cancer	4.82e-06	0.000337	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EGF—prostate cancer	4.77e-06	0.000334	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IRS1—prostate cancer	4.77e-06	0.000334	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	4.72e-06	0.00033	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—APC—prostate cancer	4.72e-06	0.00033	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IRS1—prostate cancer	4.66e-06	0.000326	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EGF—prostate cancer	4.66e-06	0.000326	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	4.63e-06	0.000324	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—INS—prostate cancer	4.57e-06	0.000319	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	4.53e-06	0.000317	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	4.47e-06	0.000313	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—INS—prostate cancer	4.47e-06	0.000312	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IGF1—prostate cancer	4.42e-06	0.000309	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	4.39e-06	0.000307	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	4.37e-06	0.000306	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IGF1—prostate cancer	4.32e-06	0.000302	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	4.3e-06	0.000301	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	4.27e-06	0.000299	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	4.24e-06	0.000297	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	4.2e-06	0.000294	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	4.19e-06	0.000293	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	4.17e-06	0.000292	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	4.15e-06	0.00029	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	4.15e-06	0.00029	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	4.11e-06	0.000287	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	4.1e-06	0.000287	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	4.06e-06	0.000284	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—FGF2—prostate cancer	4.06e-06	0.000284	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—NOS3—prostate cancer	4e-06	0.00028	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—FGF2—prostate cancer	3.97e-06	0.000278	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—NOS3—prostate cancer	3.92e-06	0.000274	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—JAK2—prostate cancer	3.89e-06	0.000272	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	3.81e-06	0.000267	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—JAK2—prostate cancer	3.81e-06	0.000266	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MDM2—prostate cancer	3.8e-06	0.000266	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	3.74e-06	0.000262	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	3.73e-06	0.000261	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MDM2—prostate cancer	3.72e-06	0.00026	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	3.7e-06	0.000259	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	3.66e-06	0.000256	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	3.61e-06	0.000253	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	3.55e-06	0.000248	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	3.47e-06	0.000243	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	3.47e-06	0.000243	CbGpPWpGaD
Levobunolol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	3.43e-06	0.00024	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CASP3—prostate cancer	3.4e-06	0.000238	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IL2—prostate cancer	3.39e-06	0.000237	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	3.39e-06	0.000237	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—IL6—prostate cancer	3.38e-06	0.000236	CbGpPWpGaD
Levobunolol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	3.36e-06	0.000235	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CASP3—prostate cancer	3.32e-06	0.000233	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IL2—prostate cancer	3.32e-06	0.000232	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CCND1—prostate cancer	3.31e-06	0.000232	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—IL6—prostate cancer	3.3e-06	0.000231	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	3.28e-06	0.000229	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CCND1—prostate cancer	3.24e-06	0.000226	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MMP9—prostate cancer	3.21e-06	0.000225	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	3.2e-06	0.000224	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	3.2e-06	0.000224	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PTEN—prostate cancer	3.19e-06	0.000223	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MMP9—prostate cancer	3.14e-06	0.00022	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	3.13e-06	0.000219	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PTEN—prostate cancer	3.12e-06	0.000219	CbGpPWpGaD
Levobunolol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	3.12e-06	0.000218	CbGpPWpGaD
Levobunolol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	3.05e-06	0.000213	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EP300—prostate cancer	3.05e-06	0.000213	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EP300—prostate cancer	2.98e-06	0.000208	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—SRC—prostate cancer	2.96e-06	0.000207	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—SRC—prostate cancer	2.9e-06	0.000203	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	2.88e-06	0.000202	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—STAT3—prostate cancer	2.86e-06	0.0002	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	2.82e-06	0.000197	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—STAT3—prostate cancer	2.79e-06	0.000195	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—MYC—prostate cancer	2.65e-06	0.000186	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	2.65e-06	0.000185	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—MYC—prostate cancer	2.6e-06	0.000182	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—EGFR—prostate cancer	2.6e-06	0.000182	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	2.59e-06	0.000181	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—EGFR—prostate cancer	2.54e-06	0.000178	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—KRAS—prostate cancer	2.45e-06	0.000172	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—KRAS—prostate cancer	2.4e-06	0.000168	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	2.25e-06	0.000158	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	2.2e-06	0.000154	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—TP53—prostate cancer	2.18e-06	0.000153	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—TP53—prostate cancer	2.13e-06	0.000149	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—IL6—prostate cancer	1.99e-06	0.00014	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—IL6—prostate cancer	1.95e-06	0.000137	CbGpPWpGaD
Levobunolol—ADRB1—Signaling Pathways—AKT1—prostate cancer	1.84e-06	0.000129	CbGpPWpGaD
Levobunolol—ADRB2—Signaling Pathways—AKT1—prostate cancer	1.8e-06	0.000126	CbGpPWpGaD
